1Romero S, Martmez A, Hernandez L, et al. Light's criteria revisited: consistency and comparison with new proposed alternative criteria for separating pleural transudates from exudates[J]. Respiration, 2000, 67 (1):18-23.
4Yokoe T. lino Y, Morishita Y. Trends of IL-6 and IL- 8 levels in patients with recurrent breast cancer; preliminary report[J]. Breast Cancer, 2000,7 ( 3 ) : 187.
2Jin HY, Lee KS, Jin SM,et al. Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion[J]. Respir Med. 2004,98 (2) : 115 - 122.
3Hada M. Report of two cases with pleural effusion and asci- tes that responded dramatically to the combination of thalido-mide, celeeoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities[J]. Gan To Kagaku Ryoho. 2004,31 (4):613-617.
4Hamed Ea, EI-Noweihi AM, Mohamed AZ. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions[J]. Respirology, 2004, 9 (1):81 -86.
5Yeh HH, Lai WW, Chen HH, etal. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion [J]. Oncogene, 2006,25(31) :4300 - 4309.
6Kaya A, Poyraz B, Celik G, et al. Vascular endothelial growth factor in benign and malignant pleural effusions[J]. Arch Bronconeumol,2005, 41 (7) :376 - 379.
7Kalomenidis I, Kollintza A, Sigala I, et al. Angiopoietin-2 levels are elevated in exudative pleural effusions[J]. Chest, 2006, 129(5):1259- 1266.
8Matsumori Y, Yano S, Goto H,et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model[J]. Oncol Res, 2006, 16( 1 ) : 15 - 26.
9Shamshiev A, Gober HJ, Donda A,et al. Presentation of the same glyeolipid by different CD1 molecules[J]. J Exp Med, 2002, 195(8):1013 -1019.
10Stenger S, Niazi KR, Modli RL. Down-regulation of CD1 on antigen-pressenting cells by infection with Myeobaeterium tuberculosis[J]. J lmmunol, 1998, 161(7):3582-3588.
6Light RW,MaegregorM I,Luchsinger PC, et al. Pleural effu- sions: the diagnostic of transudates and exudates[J]. Ann Intern Med, 1972, 77(3):507-513.
7Sun YC, Wang GF, Hu H, et al. Investigation on the diag- nostic state of pleural effusions in part of hospital of Beijing [J]. Chinese Journal of Tuberculosis and Respiratory Disea- ses, 2001, 24(2):124- 125.
8Rahman NM,AIi NJ,Brown G,et al. British Thoracic Society Pleural Disease Guideline Group. Local anaesthetic thoracos- copyz British Thoracic Society Pleural Disease Guideline [J]. Thorax,2010,65(2): 54-60.
9Wang CY, Hsiao YC, Jerng .IS, et al. Diagnostic value of proealcitonin in pleural effusions[J]. Eur J Clin Microbiol In- fect Dis,2011,30: 313-318.
10Wang CY, Hsiao YC, Jerng JS, et al. Diagnostic value of procalcitonin in pleural effusions[J]. Eur J Clin Microbiol In- Ject Dis,2011,30: 313-318.
